Skip to content
LATEST
Health

New Genetic Targets Identified for Pancreatic Cancer Treatment

Researchers identified MYC and TIGIT as key genetic targets to inhibit pancreatic cancer progression and improve the efficacy of immune-based therapies.

New Genetic Targets Identified for Pancreatic Cancer Treatment

Researchers have identified the mechanisms by which pancreatic ductal adenocarcinoma cells undergo genetic reshaping to increase aggressiveness and evade therapeutic intervention. By analyzing individual tumor cell populations, the study determined that cancer cells utilize clonal diversity to transition between states of varying malignancy.

The investigation highlights the MYC gene as a primary driver of aggressive cellular behavior. Laboratory trials demonstrated that inhibiting MYC activity can revert cancer cells to a less aggressive state, potentially increasing their vulnerability to immune system detection.

Furthermore, the study identified the TIGIT gene as a factor in immune evasion, providing a potential explanation for the historical failure of PD1-targeted immunotherapies in pancreatic cancer cases. These findings suggest that future clinical strategies should prioritize targeting these specific genetic mechanisms to disrupt tumor evolution and improve patient outcomes.

More stories

Latest news